Sir, HIV-associated nephropathy (HIVAN) is still associated with high mortality, 1 and is usually a late complication of HIV chronic infection. 2 Since 2010, a link has been strongly established between APOL1 genetic variants and HIVAN, especially in the African population. 3 A middle-aged man from Ivory Coast was admitted to hospital for a flu-like illness lasting for 1 month. He had already received several antibiotic regimens and previous malaria and HIV tests were negative. He had been on amlodipine/valsartan for many years for hypertension and his plasma creatinine level 1 month before was 1.25 mg/dL (110 lmol/L).
His weight had increased from 101 to 113 kg with pitting oedemas in the legs and frothy urine for 1 month. Diffuse small peripheral lymphadenopathies were present. Clinical examination was otherwise normal.
Biological assessment showed an acute kidney injury with indication for dialysis [serum creatinine 20.3 mg/dL (1781 lmol/L), blood urea nitrogen 40.7 mmol/L, potassium 5 mmol/L and carbon dioxide 15 mmol/L] and a nephrotic syndrome with low serum albumin (1.3 g/dL), high-level proteinuria (7 g per day) and a urinary protein/creatinine ratio of 1.72. Ultrasound found normal-sized hyperechogenic kidneys (12 cm each).
A renal biopsy showed typical HIVAN: one-third of the glomeruli were sclerotic with all but one displaying a collapsing focal segmental glomerulosclerosis (FSGS) with hypertrophic podocytes (Figure 1a) . The tubulointerstitial area revealed many cystic tubular lesions associated with a moderate inflammatory infiltrate (Figure 1b) . Acute tubular necrosis lesions and a discrete patchy fibrosis were also present. The immunofluorescence study was negative for IgA, IgG, IgM, C3, C1q and albumin.
The HIV test (ELISA) confirmed with a western blot (New Lav Blot, Bio-Rad) returned positive. The p24 antigen was negative. The initial CD4 count was 594 cells/mm 3 (17%) and the plasma HIV-1 RNA was 1.2 million (6.04 log) copies/mL. The patient tested negative for syphilis, hepatitis B and C and opportunistic infections except for a cytomegalovirus (CMV) replication (3 log DNA copies/mL). The HIV-1 strain was a CRF02_AG subtype with a CCR5 tropism, and the genotyping assay displayed no resistanceassociated mutation.
ART was quickly initiated with raltegravir and etravirine with addition of abacavir to the regimen when HLA B5701 returned negative. Dialysis was continued for 2 weeks. Considering the severity of renal failure and the nephrotic syndrome, the patient received both angiotensin-converting enzyme (ACE) inhibitors and corticosteroid therapy. Ten days after initiating treatment, plasma creatinine decreased and stabilized at about 2.3 mg/dL (200 lmol/L); the protein/creatinine ratio also decreased to 0.46.
After 6 weeks of treatment, the HIV-1 load decreased to 449 copies/mL. The CD4 count increased to 1063 cells/mm 3 (45%) with a CD4/CD8 ratio of 1.18 and lymphadenopathy disappeared.
To confirm a recent HIV infection, we used both a supplemental western-blot assay (HIV Blot 2.2, MP Biomedicals, Singapore) and an enzyme immunoassay for recent infection (IDE-V3). 4 The western blot showed the presence of antibodies to gp160, gp120 and p24, weak reactivity towards the reverse transcriptase (p66/51) and gp41, and a lack of anti-integrase (p31) (Figure 1c ). This profile corresponds to Fiebig stage V. 5 The value of P (probability of being classified as a non-recent seroconverter) in the IDE-V3 assay was 0.016, a very low value consistent with a recent HIV infection. 4 Analysis of the APOL1 gene showed that the patient was carrying two allelic variants called G1 and G2, already known to predispose to HIVAN and FSGS. The OR of developing HIVAN when carrying two APOL1 variants (G1 and/or G2) is estimated to be 29. 3 HIVAN is generally recognized as a complication of advanced HIV disease, with CD4 count ,200 cells/mm 3 characterized by rapidly progressive renal failure, proteinuria or nephrotic syndrome, urinary sediment, and an ultrasound finding enlarged, highly echogenic kidneys. 6 Nevertheless, definitive diagnosis of HIVAN is based on histological criteria.
In our case, renal biopsy was consistent with typical HIVAN as well as the improvement in renal function with efficient ART, ACE inhibitors and corticosteroids. 7 One unusual feature was the recent negative HIV test, but the Fiebig stage V profile and the IDE-V3 assay confirmed the recent infection.
Another pre-existing cause of glomerulopathy, such as FSGS, cannot be excluded here, but is unlikely. CMV-induced FSGS has rarely been described, but the immunohistochemical study on the biopsy was negative for CMV, and CMV viraemia remained stable during renal function improvement.
Rare cases of HIVAN during primary infection have been described. Three cases were published in the early 2000s, when analysis of allelic variants of the APOL1 gene was not available. [8] [9] [10] Therefore, to the best of our knowledge, this is the first report of a 
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Sir, Hepatitis C virus (HCV) is an enveloped, positive-strand RNA virus and a major causative agent of acute and chronic hepatitis worldwide. Due to error-prone replication, HCV is highly variable and, based on phylogenetic analysis, viral isolates can be grouped into seven major genotypes. In addition, genetic recombination also increases RNA virus diversity and thereby constitutes an escape strategy from the host immune response as well as antiviral treatments. For HCV, naturally occurring recombinants are rare in vivo, but probably also underestimated due to genotyping of single genomic regions in HCV diagnostics. However, several epidemiologically important hybrid strains with different breakpoints have been described 1 including the homologous recombinant of genotype 2k/1b initially discovered in St Petersburg. 2 The 2k/1b chimeric virus is found at higher prevalence in countries belonging to the former Soviet Union. 3 This variant can be missed by most routine genotyping and can only be detected by specific targets or extended V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
